276 results about "Fusion gene" patented technology

The invention relates to the technical field of spatial transcriptome data clustering analysis, and discloses a spatial transcriptome data clustering method based on progressive learning and multi-modal fusion. According to the method, a high-order structure relationship among sample points is captured by using a multilayer graph convolutional network, and various noises of gene expression data are removed to the greatest extent through comparative learning and a complementary mask mechanism; meanwhile, gene expression data, spatial position information and histological image information are ingeniously fused to the maximum degree through two times of cross attention, and then fusion feature latent representation Latent is obtained. Compared with a mainstream spatial transcriptomics clustering analysis method, the method has the advantages that clustering based on the fusion feature latent representation Latent shows higher capability and excellent clustering performance, and has remarkable robustness.

The invention provides a kit and a method for detecting common fusion genes of lymphoid leukemia based on a multiple digital PCR (Polymerase Chain Reaction) method. By constructing a synergistic effect mechanism of the primer and the fluorescent probe and optimizing matching of the primer, the probe and a fluorescent marker, non-specific binding among amplification products is effectively avoided. A composite reaction aid with a specific formula, namely a PCR enhancer, is innovatively introduced, so that the amplification efficiency and specificity of a multiple detection system are remarkably improved. According to the kit provided by the invention, the integrated detection capability on seven fluorescent channels, namely Atto 425, VIC, FAM, ROX, CY5, CY5.5 and CY7, is realized in a single-hole design. By innovatively constructing an ROX + CY5 and Atto425 + VIC dual-channel joint detection system, when the ROX and CY5 channels or Atto425 and VIC channels in the same detection hole simultaneously present positive signals, two additional detection targets can be specifically interpreted. The innovative detection strategy based on channel combination enables the kit to realize precise detection of 18 fusion genes only through two detection holes in a breakthrough manner.

The invention relates to the technical field of biology, in particular to a preparation method and application of a recombinant human long-acting interleukin-22 binding protein. The amino acid sequence of the recombinant human long-acting interleukin-22 binding protein is as shown in SEQ ID No. 1. According to the method for preparing the IL-22BP recombinant protein with high biological activity by utilizing an Escherichia coli prokaryotic expression system, a novel fusion protein is designed, a sequence for coding human IL-22BP is connected with a sequence for coding ABD to construct an IL-22BP-ABD fusion gene, the IL-22BP-ABD fusion gene is induced to be expressed in Escherichia coli, inclusion body protein is separated, and the IL-22BP recombinant protein with high biological activity is obtained. The target protein is obtained through denaturation, purification and renaturation, and the biological activity of the IL-22BP-ABD is verified through in-vivo and in-vitro experiments.

The invention relates to the technical field of plant genetic engineering, in particular to a ginkgo GbGRF2 gene and application of a GbGRF2-GbGIF2 fusion gene of the ginkgo GbGRF2 gene in plant tissue culture. According to the invention, the GbGRF2 gene coding region full length of the GRF gene family of gingko is successfully cloned from gingko, and the gene presents a specific expression mode in the regeneration process of gingko callus; the overexpression of the fusion gene of GbGRF2 and GbGRF2-GbGIF2 can significantly promote the regeneration efficiency of adventitious buds in the in-vitro culture process of plants; the gene provided by the invention has important theoretical significance and application potential in a plant tissue regeneration regulation network, and plays a key role in improving in-vitro regeneration efficiency of gymnosperm.

The invention provides a method for preparing rebaudioside M by constructing a UGT91C1-UGT76G1-SuSy fusion enzyme on the basis of an artificially constructed substrate microchannel principle and using relatively cheap raw materials to efficiently catalyze a cascade reaction. EAAAK 3 and (GGGGS) 4 are used as connecting peptides, UGT76G1 is fused at the C end of UGT91C1, SuSy is fused at the C end of UGT76G1, mass transfer of an intermediate product is enhanced, and the intermediate product is prevented from being diffused to a reaction main body. The invention also discloses a construction method of the ugt91C1-C1-ugt76G1-suusy fusion gene, a construction method of a recombinant plasmid, a construction method of a recombinant strain, a protein expression and purification method and a method for catalytically preparing a product. The ugt91C1-C1-ugt76G1-suusy fusion gene has a very good application prospect in biological industrial catalytic production.

The invention relates to the technical field of aquaculture fish vaccines, in particular to a fusion gene of grass carp NPM1a and II type reovirus VP38, recombinant protein, a composition and application. The nucleotide sequence of the fusion gene is as shown in SEQ ID NO: 1. The fusion gene is obtained by connecting grass carp NPM1a and II type reovirus VP38 through a linker sequence, a BamH restriction enzyme cutting site is added to the 5'end of the fusion sequence, and an XhoI restriction enzyme cutting site is added to the 3 'end of the fusion sequence; the sequence of the linker is as shown in SEQ ID NO: 2. The subunit vaccine of the fusion protein of the grass carp NPM1a and the II type reovirus VP38 is prepared, and indole-3-lactic acid is used as an immunopotentiator in a combined manner, so that the technical bottlenecks of low protection rate, poor intestinal mucosal barrier repairability and the like of the existing vaccine are overcome.

The invention discloses a method for evaluating the detection effect of a fusion gene detection method, and belongs to the technical field of evaluation based on the detection effect. According to the invention, a detection reference substance I and a detection reference substance II are constructed, and the detection reference substances are connected with a reference gene segment in equal molecular number proportion, so that the detection condition under the condition of equivalent reference gene expression level can be realized, and whether the sample quality reaches the detection standard or not can be deduced; the measurement of the lowest detection quantity of the fusion gene relative to the expression quantity of the reference gene is realized; the first detection reference is used for detecting sensitivity analysis of the fusion type by the detection method of the fusion gene to be detected, and the second detection reference is used for verifying whether a detection result of the detection method of the fusion gene to be detected is a false negative result or not. And the method has a very good application prospect.

The invention discloses an escherichia coli engineering bacterium for producing 5-ALA by an anaerobic fermentation method as well as a construction method and a fermentation method of the escherichia coli engineering bacterium. The engineering bacterium is constructed by taking escherichia coli (E. coli) ZX11 as a host and performing heterologous expression on 5-ALA synthetase (HemA) from rhodobacter capsulatus. In order to improve the soluble expression level of the HemA, the HemA is subjected to fusion expression with a maltose binding protein (MBP) tag. Furthermore, the engineering bacterium can also heterologously express a visual purple protein (PR) fused with the MBP tag. The construction method of the engineering bacteria comprises the following steps: sequentially cloning the MBP-HemA fusion gene and the PR gene to an expression vector and transferring into host bacteria. By utilizing the engineering bacteria provided by the invention, anaerobic fermentation can be carried out in a culture medium taking glucose as a carbon source, and 5-ALA can be efficiently synthesized. The invention provides an effective way for realizing green and energy-saving anaerobic biological manufacturing of 5-ALA.

The invention discloses a rapid detection method for traumatic brain injury by fusing genetic engineering and quantum dots, and relates to the technical field of traumatic brain injury detection. The method comprises the following steps: acquiring a suspected patient biological sample, extracting biomolecule components, and comparing the biomolecule components with a healthy population biomolecule database to obtain related differential expression molecules. A specifically recognizable recombinant antibody is constructed by genetic engineering, and is connected with a quantum dot through a coupling reaction to prepare a detection probe. The probe and a biological sample are mixed and reacted, and the intensity of a fluorescence signal generated by combination is collected by a fluorescence detection device. A standardized signal value is obtained through signal processing algorithm noise reduction and feature extraction, and a preliminary detection result is determined by combining a bioinformatics database evaluation sample. And finally, according to the differential expression molecule, the standardized signal value and the preliminary result, analyzing a data change trend in a preset time window by using a multivariable statistical model, and generating a diagnosis report. According to the method, various technologies are fused, and a new path is provided for traumatic brain injury detection.

The invention provides a multi-stream fusion gene sequence prediction method based on Mama and a double-coding strategy, and aims to improve semantic understanding and modeling capability of DNA sequences, so as to improve accuracy and generalization performance of protein expression value prediction. The method comprises the following steps: synchronously processing a forward chain and a reverse complementary chain of a DNA sequence: carrying out word segmentation and vectorization on the reverse complementary chain by adopting BPE coding to capture a semantic fragment; and the forward chain is subjected to one-hot coding and is linearly mapped into dense representation. Deep features of the two features are extracted through Mama Block and then are spliced and fused, then LSTM is input to model context dependence, and finally an expression value is output through a full connection layer. According to the method, the problems that biological semantic fragments are difficult to capture by One-Hot coding and functional domains are likely to be split by BPE coding are effectively solved. On the basis of a Mama framework, a local structure and global semantics are effectively combined, and the method is good at capturing long-distance dependence while low calculation complexity is kept, and is suitable for tasks such as gene design and protein expression regulation and control.

The invention relates to an expression cassette and a method for producing humanized triple helix collagen by using the expression cassette, and belongs to the technical field of genetic engineering. The expression cassette sequentially comprises a promoter sequence, a fusion gene and a terminator sequence from upstream to downstream, the fusion gene comprises nucleotide fragments A, B and C, each fragment comprises an immutable region and a variable region, and the variable region is selected from I, II, III, IV and XVII type human collagen. A kex2 protease recognition site KR is introduced into an expression box, so that an expression product can be subjected to trisection cutting, and three equal-length peptide chains with a triple-helix basic structure are formed. The invention also provides a recombinant humanized collagen with a self-assembled triple helix structure and a production method thereof, and the method comprises the following steps: preparing a recombinant expression vector containing the expression cassette and a proline hydroxylase expression vector, and transferring the two expression vectors into competent cells for co-expression. The method can be used for producing the recombinant humanized collagen with the self-assembled triple-helix structure, and has a good application prospect.

The invention discloses a pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector as well as a construction method and application of the pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector. The construction method comprises the following steps: mixing an mCherry gene segment and an IRES2 gene segment which are respectively obtained by PCR (Polymerase Chain Reaction) amplification in equal mass, then carrying out fusion amplification to obtain an IRES2-mCherry fusion gene segment, and carrying out homologous recombination on the IRES2-mCherry fusion segment and a pCDNA-3xHA-hTERT linearization vector. On the basis of a pCDNA-3xHA-hTERT stent vector, a pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector with red fluorescence is successfully constructed, and the fusion expression vector can be used as a fusion expression vector of the pCDNA-3xHA-hTERT-IRES2. The construction method is simple and efficient, enzyme digestion is not needed, and the constructed pCDNA-3xHA-hTERT-IRES2-mCherry fusion expression vector can be subsequently used for transfecting bovine endometrial epithelial cells, so that the immortalized bovine endometrial epithelial cells are obtained.

The application relates to a sarcoma fusion gene nanopore sequencing primer set and application thereof, wherein the primer set comprises five pairs of specific primers (Primer 1-5) with fixed sequences, each primer follows the design principle of 18-25 bp in length, 40%-60% in GC content and strict matching of a target sequence at a 3' end, and the length of an amplification product is 300-800 bp, which is suitable for nanopore sequencing. Through qPCR verification, the primer set has single-peak melting curves, close-to-100% amplification efficiency, strong specificity and excellent amplification performance.

Compositions and methods for knocking down the expression of an EWSR1-ATF1 fusion gene and / or an EWSR1-CREB1 fusion gene in a subject are disclosed herein. In some embodiments, the composition comprises an expression vector comprising a bifunctional short hairpin RNA (bi-shRNA) sequence specific for knockdown of an EWSR1-ATF1 fusion gene and / or an EWSR1-CREB1 fusion gene.

The invention discloses an organ-like drug resistance prediction method and device and a storage medium, and relates to the technical field of bioinformatics, and the method comprises the steps: S1, constructing an initial prediction model; s2, acquiring a training data set; s3, training an optimization prediction model; s4, acquiring related data of a to-be-predicted drug; s5, obtaining a prediction result of the drug resistance of the to-be-predicted drug; according to the method, the drug resistance of the organoid to the drug can be predicted more accurately. By fusing multi-dimensional features of gene mutation, target mutation and drug functional groups, the understanding and learning ability of the model to the drug resistance mechanism is enhanced, and the reliability of drug resistance prediction is improved. The method not only can accurately capture key information of influence of gene and target mutation on drug resistance, but also can highlight unique mutant genes of the organoid on drug resistance by comparing feature differences of the organoid and a common cell line, so that an efficient and accurate calculation framework is provided for drug resistance detection.

The application discloses a kind of methods, systems, equipment and media for analyzing EML4-ALK fusion gene type, belong to the technical field of fusion gene detection.The method comprises obtaining RNA sequencing data of a sample to be tested;According to the primer combination coverage area, obtain the primer coverage area sequence file;The RNA sequencing data is compared with the primer coverage area sequence file for the second time;The number of sequencing data that can be aligned to the exon sequence of two genes at the same time is counted.Using the method and system of the application, unknown type of fusion gene can be accurately detected, which is more conducive to the development of downstream research on the related mechanism and function of fusion gene.

The invention relates to an intron variant capable of accurately splicing and enhancing gene transcription and application of the intron variant, and belongs to the technical field of biological breeding, the intron variant is a variant of a Cat1mu intron, the Cat1mu intron has a nucleotide sequence as shown in SEQ ID NO.2, and the nucleotide sequence of the intron variant is formed by mutating base AG at the 182th to 183th sites of the sequence as shown in SEQ ID NO.2 into tG, Ac, At, cG, Aa, ta, tt, tc, cc, ct or ca. According to the present invention, the sequence analysis and the saturation mutation are performed on the Cat1mu, the screening is performed to obtain the Cat1mu series variant Cat1mu2-12, the accurate splicing effect of the Cat1mu2-12 during the fusion gene expression process is verified, and the Cat1mu6, the Cat1mu7, the Cat1mu8 and the Cat1mu10 can further enhance the fusion gene expression effect.

The invention provides an application of an ASPL-TFE3 fusion gene in preparation of a medicine for enhancing the curative effect of an immune checkpoint inhibitor. The nucleotide sequence of the fusion gene is as shown in SEQ ID NO: 1 or SEQ ID NO: 2. The invention relates to the field of tumor immunotherapy, in particular to a method for regulating and controlling expression and activity of TFE3 through ASPL-TFE3 fusion protein to enhance tumor cell autophagy and immune cell permeation, and the tumor treatment effect of an immune checkpoint inhibitor can be improved.

This invention belongs to the field of acute lymphoblastic leukemia (ALL) technology and discloses an ALL scoring system. The system divides the entire treatment cycle into three major phases: induction remission, consolidation therapy, and maintenance therapy. Each phase is further subdivided into sub-phases, forming a two-tiered data acquisition architecture. During data collection, baseline data such as age and fusion genes are included, along with dynamic data such as the rate of MRD decline and drug exposure concentration. Simultaneously, anchor triggering mechanisms are set at different sub-phases, making the risk score more closely aligned with the patient's real-time condition and providing a more accurate reference for clinical treatment strategy selection. The feature adaptation module matches subtype-specific biomarkers and analyzes the interaction between rare subtypes and comorbidities. The matching module calls upon a three-dimensional protocol library to select standardized protocols for common subtypes, targeted protocols for rare subtypes, and dose adjustment or drug substitution protocols for patients with comorbidities, matching more suitable protocols for different patients.

The application discloses a gene regulation relationship prediction method based on matrix enhancement and feature fusion, and comprises the following steps: 1, obtaining N genes G and their regulation relationship R; 2, calculating the directed adjacency matrix of the genes according to R; 3, generating the similarity matrix of the source genes and normalizing the similarity matrix; 4, generating the similarity matrix of the target genes and normalizing the similarity matrix; 5, processing the normalized source gene similarity matrix and the normalized target gene similarity matrix respectively by adopting an EASNN method, and performing matrix enhancement processing on the adjacency matrix; 6, generating the covariance matrix Co of the genes, and selecting the neighborhood gene pair set of any gene pair according to Co; 7, obtaining the total histogram set Mg of each gene pair according to G; 8, obtaining the total enhanced histogram set Ma of each gene pair; and 9, constructing a CNN network to obtain the probability that a regulation relationship exists between each gene pair. The application can effectively fuse the gene expression features and the enhanced network structure features, so that the regulation relationship between the genes can be more accurately predicted.

The application discloses a preparation method of a recombinant ternary fusion protein dressing with epidermal cell activation function. The dressing is a fusion protein designed based on the research on the functions and properties of COL3A1 and IFN-kappa proteins by international peers and the laboratory. The specific method is that the fusion gene fragment of the covalent connection of COL3A1 and IFN-kappa with GGSGG as a linker is obtained by using overlap extension PCR technology, and a 6×His label is added. The target gene is cloned into a prokaryotic expression vector pET30 (modified in the laboratory) to obtain the fusion protein COL3A1-IFN-kappa with an MBP label. After expansion culture, the MBP-IFN-kappa-COL3A1 with a purity of more than 90% can be obtained through Ni-NTA column affinity chromatography. We verified the resistance of the fusion protein to salmonella in THP-1 cells, and verified the effect of the fusion protein on promoting wound healing and resisting salmonella infection on mice. Finally, it is proved that the MBP-IFN-kappa-COL3A1 has good uniformity, is easy to purify, has high activity, has no side effects, and is very suitable for being used as an epidermal cell activation dressing.

In some embodiments, a computer-implemented method of detecting a presence of a predetermined fusion gene in a biological sample is provided. A computing system generates an alignment of a read sequence to a reference genome. The alignment includes a first alignment result and a second alignment result. The computing system determines a breakpoint location indicated by the first alignment result and the second alignment result, distances between coordinates of the breakpoint location and coordinates of one or more expected breakpoint locations associated with the predetermined fusion gene, a gap size value and an overlap size value. In response to determining that the gap size value is less than a gap size value threshold, the overlap size value is less than an overlap size value threshold, and the distances are less than a breakpoint distance threshold, the computing system generates an indication of the presence of the predetermined fusion gene.

This invention provides a method for creating a transgenic papaya strain highly resistant to papaya ringspot virus and papaya mosaic virus. The method involves using PRSV and PLDMV of papaya... CP The fusion gene fragment expression cassette and the selection marker gene expression cassette were placed in two separate T-DNA domains and inserted into a plant expression vector. This vector was then introduced into papaya to obtain a papaya line without the selection marker; alternatively, PRSV and PLDMV were used. CP A fusion gene expression cassette and its reverse sequence were tandemly inserted into a plant expression vector, which was then introduced into papaya to obtain... CP A papaya strain with inversely linked gene expression cassettes. The marker-free papaya of this invention does not contain selection markers, effectively improving safety; CP Papaya with inversely linked gene expression cassettes does not require further homozygosity to enhance disease resistance.

The invention discloses a method for adding name information to a protein or a strain or a cell and enabling a name to be never decayed and application. The method comprises the following steps: creating a name for the protein or the strain or the cell; representing each character in the name of the protein or strain or cell with a specific DNA sequence fragment; connecting the DNA sequence fragments in series to form a tandem DNA sequence; fusing the tandem DNA sequence with name information and the DNA sequence of the protein into a fusion gene; constructing the fusion gene into an expression vector, and transforming the vector into a host strain or cell; and checking the expression condition of the fusion protein in the strain or the cell. According to the invention, tandem DNA or fusion protein with names or strains or cells containing name information can be obtained. The name information of the fusion protein can be read through DNA sequencing or indirectly verified through expression of the fusion protein. The method has the advantages that a name can be added to the protein or the strain or the cell, and the protein or the strain or the cell with the proprietary intellectual property right can be obviously proved compared with a common DNA information storage technology. Besides, the protein, the strain and the cell are named and DNA with name information is added, so that the protein, the strain and the cell are personified, and the protein, the strain and the cell with names are more interesting. And the name can be never decayed along with passage of strains and cells.

The invention discloses a preeclampsia biomarker and an application of the preeclampsia biomarker. The preeclampsia biomarker comprises at least one of a fusion gene PSPC1-MRPS31P2 and a fusion gene LINC00630-AL035494. The preeclampsia biomarker can be used for detecting preeclampsia. The preeclampsia biomarker provided by the invention can provide a non-invasive diagnosis scheme for clinical prenatal preeclampsia, and preeclampsia specific high-expression fusion genes (PSPC1-MRPS31P2 and LINC00630-AL035494) in peripheral blood of a pregnant woman are detected through real-time quantitative PCR (Polymerase Chain Reaction), so that preeclampsia early prediction, disease diagnosis and monitoring of the state of a patient in the illness period are realized; and in combination with the existing clinical diagnosis scheme, the accuracy of pre-eclampsia diagnosis is improved.

The invention relates to the technical field of fusion gene detection, and discloses a high-throughput detection platform of a thyroid cancer specific fusion gene CCDC6. According to the detection platform disclosed by the invention, high-throughput and high-sensitivity detection on the thyroid cancer CCDC6 fusion gene is realized through a technical scheme of combining sample enrichment and deep learning recognition. Through combination of the sample enrichment module and the deep learning recognition module, the sample enrichment module promotes high-sensitivity recognition of the deep learning recognition module, an end-to-end integrated solution is provided, a large number of samples can be processed in one-time operation, the result can be automatically interpreted, and the detection efficiency and accuracy of the CCDC6 fusion gene are remarkably improved.

This invention provides the application of IGF2BP3 as a target in the preparation of therapeutic drugs for fusion gene leukemia, specifically in the preparation of mRNA-highly stable fusion gene leukemia. The highly stable mRNA fusion genes include, but are not limited to, PAX5-ETV6 and STK38-PXT1 fusion genes. The drugs include IGF2BP3 gene-specific interfering RNA and IGF2BP3 inhibitors, including but not limited to venetoclax. This invention is the first to propose the use of IGF2BP3-targeted drugs for the treatment of mRNA-highly stable fusion gene leukemia; it not only reveals the role of IGF2BP3 in the oncogenic function of fusion genes but also provides a new therapeutic target and effective drug for this type of fusion gene leukemia, offering the possibility of further improving the clinical efficacy, prognosis, and survival of leukemia patients.

This invention discloses an oral vaccine against carp spring viremia virus, its preparation method, and its application. The oral vaccine is constructed by linking a carp spring viremia virus antigen protein and a Yellow River carp defensin protein via a flexible linker to form a fusion protein, which is then expressed in *E. coli* and enriched using a biological vector. The gene sequence encoding this fusion protein includes a truncated fragment of the carp spring viremia virus antigen protein gene (64-1389 bp), a fragment of the Yellow River carp defensin protein gene (70-201 bp without the signal peptide), and a flexible linker fusion gene connecting the two gene fragments. Compared with previously reported anti-SVCV vaccines, the oral vaccine against carp spring viremia virus prepared in this invention does not harm the fish during the entire immunization process, is simple to operate, safe and stable, and has a higher protection rate. Therefore, this oral vaccine provides broad prospects for the prevention and control of carp spring viremia.